Status:
UNKNOWN
Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
Lead Sponsor:
Centre National de Greffe de Moelle Osseuse
Conditions:
Graft vs Host Disease
Eligibility:
All Genders
16-45 years
Phase:
PHASE3
Brief Summary
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also...
Eligibility Criteria
Inclusion
- Age: \> 16 years and \< 46 years
- Geno-identical allogeneic bone marrow transplantation
- Myeloablative conditioning regimen
- Haematological malignancies and acquired aplastic anemia
- Written and informed consent
Exclusion
- ECOG performance score \> 2
- T-cell depletion
- Serum creatinine level \> 133 µmol/L
- Abnormal liver function
- Positive HIV test
- Pregnant women
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00207792
Start Date
July 1 2005
Last Update
November 6 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre National de Greffe de Moelle Osseuse
Tunis, Tunisia